Skip to Main Content

Paper Details

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
Mult Scler
15
2018
Author NameAffiliation
Lisanne J BalkVU University Medical Center
  • 1 - 1

Datasets

Release 1.2